Predicted protein targets (top 7)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | ADRB1 | P08588 | 1/20 | 0.49 |
| ▸ | DNMT1 | P26358 | 1/20 | 0.49 |
| ▸ | POLB | P06746 | 2/20 | 0.37 |
| ▸ | NLRP3 | Q96P20 | 1/20 | 0.36 |
| ▸ | ABCB1 | P08183 | 4/20 | 0.34 |
| ▸ | EP300 | Q09472 | 2/20 | 0.34 |
| ▸ | ABCG2 | Q9UNQ0 | 1/20 | 0.34 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL7915397 | 0.78 | DNMT1 (0.58) | ADRB1DNMT1POLBABCB1ABCG2 | |
| SCHEMBL2984540 | 0.77 | POLB (0.56) | ADRB1DNMT1POLBNLRP3 | |
| SCHEMBL5369313 | 0.77 | POLB (0.56) | ADRB1DNMT1POLBNLRP3 | |
| SCHEMBL19470016 | 0.76 | DNMT1 (0.61) | ADRB1DNMT1POLB | |
| Decitabine SCHEMBL3394324 | 0.74 | DNMT1 (0.75) | ADRB1DNMT1 | |
| SCHEMBL10064053 | 0.74 | DNMT1 (0.70) | ADRB1DNMT1POLB | |
| SCHEMBL16366026 | 0.73 | DNMT1 (0.74) | ADRB1DNMT1POLB | |
| SCHEMBL10064225 | 0.73 | DNMT1 (0.74) | ADRB1DNMT1POLB | |
| SCHEMBL14420389 | 0.73 | ADRB1 (0.55) | ADRB1DNMT1POLB | |
| SCHEMBL5357283 | 0.72 | POLB (0.60) | POLB |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20210361777-A1 | PHARMACEUTICAL PRODRUGS AND METHODS OF THEIR PREPARATION AND USE | CEPHALON LLC | 2021-11-25 | — | — | US | disclosed |
| US-11071789-B2 | Pharmaceutical prodrugs and methods of their preparation and use | CEPHALON, INC. (US) | 2021-07-27 | — | — | US | disclosed |
| US-20190240348-A1 | PHARMACEUTICAL PRODRUGS AND METHODS OF THEIR PREPARATION AND USE | CEPHALON, INC. (US) | 2019-08-08 | — | — | US | disclosed |
| WO-2018013783-A1 | PHARMACEUTICAL PRODRUGS AND METHODS OF THEIR PREPARATION AND USE | CEPHALON, INC. (US) | 2018-01-18 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20190240348-A1 | PHARMACEUTICAL PRODRUGS AND METHODS OF THEIR PREPARATION AND USE | CYP2C19, UGT1A1, CYP2C9 | ADRB1 1328/4885DNMT1 4035/4885POLB 1942/4885 |
| US-20210361777-A1 | PHARMACEUTICAL PRODRUGS AND METHODS OF THEIR PREPARATION AND USE | CYP2C19, UGT1A1, CYP2C9 | ADRB1 1273/4885DNMT1 3917/4885POLB 1891/4885 |
| US-11071789-B2 | Pharmaceutical prodrugs and methods of their preparation and use | CYP2C19, UGT1A1, CYP2C9 | ADRB1 1328/4885DNMT1 4035/4885POLB 1942/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.